Plain-English translation of NCT06835725 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tests whether prostate stereotactic ablative radiotherapy (SABR) โ a precise form of radiation therapy โ works better when given in just 2 sessions over 2 weeks compared to the standard 5 sessions over 2 weeks. Researchers want to know if the shorter schedule is equally effective at controlling cancer while potentially causing fewer side effects on bowel and sexual function.
The shorter 2-session radiation schedule could be more convenient for patients and use fewer medical resources, but doctors need a head-to-head comparison to confirm it's as safe and effective as the longer 5-session approach.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you enroll, you'll have fiducial markers (tiny seeds) placed in your prostate and a hydrogel spacer inserted to protect nearby tissues. Then you'll receive either 2 or 5 radiation sessions over 2 weeks โ you won't know which group you're in until after you're randomly assigned. After treatment, you'll have follow-up visits to monitor for side effects and check how well the cancer is controlled.
AI-generated summary from trial data ยท Jul 15, 2026 ยท Not medical advice
Canada